TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33637835

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic (risperidone or paliperidone)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 62
Study: 36131307

Group type: EXPERIMENTAL
Intervention: Training intervention to improve the management of vertigo in primary care
Number of subjects: 0
Study: 33769293

Group type: EXPERIMENTAL
Intervention: Blended Acceptance and Commitment Therapy (ACT)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Face-to-face Cognitive Behavioral Therapy (CBT)
Number of subjects: 314
Study: 35435943

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33303934

Group type: EXPERIMENTAL
Intervention: Tape measure for Fingertip-to-Floor test (FtF)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tape measure for Lateral Inclination test (LI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Digital inclinometer for Retroflexion of the trunk (RF)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Digital inclinometer for Shoulder test (ST)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Digital inclinometer for Thomas test (TT)
Number of subjects: 22
Study: 33073745

Group type: EXPERIMENTAL
Intervention: DBT + CALMA
Number of subjects: 18

Group type: COMPARATOR
Intervention: DBT
Number of subjects: 18
Study: 32791318

Group type: EXPERIMENTAL
Intervention: PriCARE intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study: 34742136

Group type: EXPERIMENTAL
Intervention: n3 PUFA (930 mg EPA + 660 mg DHA)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 156
Study: 32089006

Group type: EXPERIMENTAL
Intervention: Alirocumab (75-150 mg every 2 weeks)
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Control (placebo/ezetimibe)
Number of subjects: 4983

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983
Study: 35239547

Group type: EXPERIMENTAL
Intervention: 1600 mg single-dose oral cannabidiol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33076885

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 138

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 138
Study: 35759877

Group type: EXPERIMENTAL
Intervention: Multimodal speech-gesture (MSG) training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study: 32053276

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIg)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Careful observation
Number of subjects: 179
Study: 36427629

Group type: EXPERIMENTAL
Intervention: Adaptive computerized cognitive training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-adaptive computerized cognitive training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined arms (adaptive and non-adaptive)
Number of subjects: 90
Study: 32800818

Group type: EXPERIMENTAL
Intervention: Shared-care clinic attendance (n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Shared-care clinic
Number of subjects: 42
Study: 34859422

Group type: EXPERIMENTAL
Intervention: Zhang's guideline
Number of subjects: 3604

Group type: COMPARATOR
Intervention: WHO partograph
Number of subjects: 3604
Study: 36264696

Group type: EXPERIMENTAL
Intervention: Interdisciplinary discharge planning
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard discharge planning)
Number of subjects: 70
Study: 34805400

Group type: EXPERIMENTAL
Intervention: Aram Video Stylet
Number of subjects: 30

Group type: COMPARATOR
Intervention: McGrath® MAC video laryngoscope
Number of subjects: 30
Study: 36139496

Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Bifidobacterium longum, Lactobacillus helveticus, and Lactiplantibacillus plantarum
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 22
Study: 32653074

Group type: EXPERIMENTAL
Intervention: Medium-dose MF–IND–GLY (80 μg, 150 μg, 50 μg)
Number of subjects: 3092

Group type: EXPERIMENTAL
Intervention: High-dose MF–IND–GLY (160 μg, 150 μg, 50 μg)
Number of subjects: 3092
Study: 34218336

Group type: EXPERIMENTAL
Intervention: PR-ESSENCE intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 108
Study: 34214682

Group type: EXPERIMENTAL
Intervention: Nonviable probiotic lysate (BL) of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 32531956

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) - complete abstinence from food intake for 16 hours per day (20:00 p.m. to 12:00 a.m.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF)
Number of subjects: 45
Study: 35341180

Group type: EXPERIMENTAL
Intervention: Multimedia badminton teaching (experimental class)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional badminton teaching (control class)
Number of subjects: 82
Study: 33161162

Group type: COMPARATOR
Intervention: Minocycline treatment
Number of subjects: 207
Study: 32289681

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39
Study: 33970358

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI)
Number of subjects: 0
Study: 32569284

Group type: EXPERIMENTAL
Intervention: Biofeedback-enhanced therapeutic exercise video game intervention
Number of subjects: 19
Study: 36498437

Group type: EXPERIMENTAL
Intervention: Intensive educational program led by nurses
Number of subjects: 131

Group type: COMPARATOR
Intervention: Routine health education and follow-up
Number of subjects: 131
Study: 32662833

Group type: EXPERIMENTAL
Intervention: Yoga or Physical Therapy (PT)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Self-care book
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Yoga or PT (with pain medication)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Yoga or PT (without pain medication)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Yoga or PT (with low fear avoidance beliefs)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Yoga or PT (with high fear avoidance beliefs)
Number of subjects: 299
Study: 32800383

Group type: EXPERIMENTAL
Intervention: Surufatinib 250 mg capsules in the fasted state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surufatinib 250 mg capsules in the fed state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surufatinib 250 mg capsules (both fasted and fed states)
Number of subjects: 24
Study: 35180798

Group type: EXPERIMENTAL
Intervention: Plastic stent
Number of subjects: 104

Group type: COMPARATOR
Intervention: No stent
Number of subjects: 104
Study: 34435440

Group type: EXPERIMENTAL
Intervention: SMS+PN
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: SMS-only
Number of subjects: 752
Study: 33026755

Group type: EXPERIMENTAL
Intervention: HQ 4%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CTB
Number of subjects: 18
Study: 33207981

Group type: EXPERIMENTAL
Intervention: Caretoon approach (illustrated and curiosity-driven public engagement campaign)
Number of subjects: 18788

Group type: COMPARATOR
Intervention: Standard approach (non-illustrated ad and survey)
Number of subjects: 18788
Study: 35633431

Group type: COMPARATOR
Intervention: Testosterone treatment for one year in men aged ≥ 65 years
Number of subjects: 1795

Group type: COMPARATOR
Intervention: Testosterone treatment for two years in men aged 50–74 years
Number of subjects: 1795
Study: 33276013

Group type: EXPERIMENTAL
Intervention: INSIGHT Responsive Parenting (RP) intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 232
Study: 34117564

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel (35% HP, commercial gel)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35% HP with 2% chitosan (35% HP + chitosan)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35% HP and calcium (35% HP + Ca, commercial gel)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35% HP + Ca + 2% chitosan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control (unbleached)
Number of subjects: 40
Study: 34013852

Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioural Therapy (ICBT)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (GCBT)
Number of subjects: 165
Study: 34106473

Group type: EXPERIMENTAL
Intervention: Short 3-item version of the Montreal Cognitive Assessment (MoCA) administered by telephone
Number of subjects: 1069
Study: 32073990

Group type: EXPERIMENTAL
Intervention: PRP+CDP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LLLT+CDP
Number of subjects: 45

Group type: COMPARATOR
Intervention: CDP
Number of subjects: 45
Study: 32213163

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neostigmine (50 mcg/kg plus 10 mcg/kg of atropine)
Number of subjects: 41
Study: 35833308

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional wound treatment
Number of subjects: 221
Study: 33440046

Group type: EXPERIMENTAL
Intervention: Exclusive enteral nutrition (EEN) for 7 days along with standard of care (SOC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 62
Study: 35452417

Group type: EXPERIMENTAL
Intervention: Curcumin (Cur)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 107

Group type: COMPARATOR
Intervention: Wnt/β‐catenin pathway inhibitors
Number of subjects: 107
Study: 33377185

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-Levosimendan (Control)
Number of subjects: 123
Study: 35585593

Group type: EXPERIMENTAL
Intervention: Shared meditation intervention (12 weekly sessions of 1.5 hours and a half-day retreat)
Number of subjects: 30
Study: 32644104

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based nCRT
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based nCRT with oxaliplatin
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant chemotherapy
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant chemotherapy with oxaliplatin
Number of subjects: 1232
Study: 34848127

Group type: EXPERIMENTAL
Intervention: Posterior tibial and sural nerve blocks with bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 48
Study: 34528723

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg, orally, twice daily for 72 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 35034194

Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (FMD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal Diet (ND)
Number of subjects: 24
Study: 33413727

Group type: EXPERIMENTAL
Intervention: 7.5 g of salmon fish protein/d
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 35333140

Group type: EXPERIMENTAL
Intervention: Proactive interdisciplinary and virtual review of patients discharged after hospitalization for COPD exacerbation
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 352
Study: 32894231

Group type: EXPERIMENTAL
Intervention: DynamX Novolimus‐Eluting Coronary Bioadaptor System
Number of subjects: 50
Study: 35712916

Group type: EXPERIMENTAL
Intervention: Guided Self-Help (GSH) program, 14 individual sessions over 6 months, 5.3 hours of treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Family-based behavioral treatment (FBT), 20 group-based sessions over 6 months, 20 hours of treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combined results from both groups
Number of subjects: 164
Study: 32381793

Group type: EXPERIMENTAL
Intervention: 660 nm diode laser applied for 1 minute on the surgical site
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no laser application)
Number of subjects: 50
Study: 36396443

Group type: EXPERIMENTAL
Intervention: Lactoferrin
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study: 33401238

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1 of body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 14
Study: 32129558

Group type: EXPERIMENTAL
Intervention: ATOP Psychological Health
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: ATOP Physical Health
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: ATOP Quality of Life
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: ATOP substance use, employment, education and child care items
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Tobacco use, Psychological Health, Physical Health and Quality of Life
Number of subjects: 128
Study: 35691974

Group type: EXPERIMENTAL
Intervention: Alpha/Theta Ratio Neurofeedback Training (ATR NFT), 10 sessions, 2-3 sessions per week
Number of subjects: 8
Study: 34387126

Group type: EXPERIMENTAL
Intervention: Cardiac neuromodulation therapy (CNT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: CNT inactive (Control)
Number of subjects: 47
Study: 32303203

Group type: EXPERIMENTAL
Intervention: Alerta Alcohol programme (intervention group)
Number of subjects: 1247

Group type: COMPARATOR
Intervention: No active intervention (control group)
Number of subjects: 1247
Study: 36253171

Group type: EXPERIMENTAL
Intervention: Parent-implemented repeated reading training (RR group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: General training based on a summer vacation workbook (SVW group)
Number of subjects: 22
Study: 33494831

Group type: EXPERIMENTAL
Intervention: Guided online intervention (6-week duration)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waiting list control (6-week duration)
Number of subjects: 18
Study: 36038256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day caffeine citrate
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day caffeine citrate
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day caffeine citrate
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 20 mg/kg/day caffeine citrate
Number of subjects: 132
Study: 34018006

Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection of triamcinolone acetonide (Kenalog)
Number of subjects: 1471
Study: 33001143

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, treatment discontinuation, or withdrawal
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 104
Study: 32170761

Group type: EXPERIMENTAL
Intervention: HBV integration at the TERT promoter
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: HBV enhancer I (EnhI)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Stable knockdown of ELF4
Number of subjects: 95
Study: 35373274

Group type: EXPERIMENTAL
Intervention: Trametinib (MEK1/2 inhibitor)
Number of subjects: 0
Study: 34830632

Group type: EXPERIMENTAL
Intervention: Real-time dosimetry monitoring system (Raysafe)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard radiation shield alone (control group)
Number of subjects: 700
Study: 33122670

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (simulated night shifts)
Number of subjects: 0
Study: 35658685

Group type: EXPERIMENTAL
Intervention: Wound closure with a vessel loop (n = 19)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wound closure without a vessel loop (standard, n = 28)
Number of subjects: 47
Study: 32591417

Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray
Number of subjects: 124
Study: 35699261

Group type: COMPARATOR
Intervention: NRD.E1 (300 to 1200 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRD.E1 (300 mg once daily for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NRD.E1 (40 mg under fed and fasted conditions)
Number of subjects: 0
Study: 33627370

Group type: EXPERIMENTAL
Intervention: Insomnia prevention program (4 weekly sessions)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Nonactive control group
Number of subjects: 242
Study: 35672057

Group type: EXPERIMENTAL
Intervention: Chemotherapy following a dose adjusted EPOCH‐R regimen
Number of subjects: 1
Study: 32179059

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 33279779

Group type: EXPERIMENTAL
Intervention: Mesalamine induction therapy
Number of subjects: 726
Study: 32660869

Group type: EXPERIMENTAL
Intervention: Trofinetide 70 mg/kg twice daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trofinetide 35 mg/kg twice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 34326006

Group type: EXPERIMENTAL
Intervention: PIEZO-ICSI
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard ICSI
Number of subjects: 69
Study: 36323462

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 80
Study: 32480252

Group type: EXPERIMENTAL
Intervention: lidocaine/craving
Number of subjects: 33

Group type: COMPARATOR
Intervention: saline/craving
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: lidocaine/relax
Number of subjects: 33
Study: 35579159

Group type: EXPERIMENTAL
Intervention: NanoBEO (essential oil of bergamot delivered via a nanotechnology-based system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34464503

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients with cancer
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Matched controls (cancer-free)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Non-Hodgkin lymphoma
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Lung cancer
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Breast cancer
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Colon-rectum cancer
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Kidney cancer
Number of subjects: 1425
Study: 34923163

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 389
Study: 33298197

Group type: EXPERIMENTAL
Intervention: Child dietary diversity
Number of subjects: 512

Group type: COMPARATOR
Intervention: Food insecurity
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Mothers' age and education
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Place of residence and sex of household head
Number of subjects: 512
Study: 35568194

Group type: EXPERIMENTAL
Intervention: BNP <200 pg/mL (low)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: BNP 200 to <400 pg/mL (moderate)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: BNP ≥400 pg/mL (high)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Edoxaban 15 mg
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 34684135

Group type: EXPERIMENTAL
Intervention: Task-Specific Training after Cognitive Sensorimotor Exercise (TST after CSE), n = 13
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Task-Specific Training (TST), n = 12
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional physical therapy training (control group), n = 12
Number of subjects: 37
Study: 32596882

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 46
Study: 34766586

Group type: EXPERIMENTAL
Intervention: HRVBF (Heart Rate Variability Biofeedback)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (simple breathing at rest)
Number of subjects: 45
Study: 34735740

Group type: EXPERIMENTAL
Intervention: Psychodynamic treatment for BPD
Number of subjects: 39
Study: 33289280

Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low-flow oxygen
Number of subjects: 74

Group type: COMPARATOR
Intervention: High-flow air
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low-flow air
Number of subjects: 74
Study: 37855897

Group type: EXPERIMENTAL
Intervention: SP TFL with 200 μm fiber
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: SP TFL with 150 μm fiber
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ho:YAG with 200 μm fiber
Number of subjects: 96
Study: 32808553

Group type: EXPERIMENTAL
Intervention: Workplace Support for Health (WSH) scale
Number of subjects: 2820
Study: 35860900

Group type: EXPERIMENTAL
Intervention: Core stability exercise program (8-week duration)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 33528679

Group type: EXPERIMENTAL
Intervention: Three sessions per week
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two sessions per week
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 32331879

Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (2.2 mg/kg of BW)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Isotonic sterile saline solution
Number of subjects: 68
Study: 33492346

Group type: EXPERIMENTAL
Intervention: Family media use plan
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1520
Study: 34856702

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) group
Number of subjects: 60